Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: A potentially promising tumor vaccine

Vaccine

Volumn 30, Issue 23, 2012, Pages 3395-3404

  Niu, Bai lin ^a   Du, Hui min ^a   Shen, Hua ping ^a   Lian, Zheng rong ^a   Li, Jin zheng ^a   Lai, Xing ^a   Wei, Si dong ^a   Zou, Li quan ^b   Gong, Jian ping ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b The 324 Hospital of PLA   (China)

Author keywords

Cancer vaccine; Cellular immunotherapy; Cytotoxicity; Dendritic cells; Epitopes; Telomeres and telomerase

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA DRB1 ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR VACCINE;

ARTICLE; CANCER CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MYELOID DENDRITIC CELL; PHENOTYPE; PRIORITY JOURNAL;

ADULT; CANCER VACCINES; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; EPITOPES; HLA ANTIGENS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VACCINES, SYNTHETIC;

EID: 84859819967     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.045     Document Type: Article

References (45)

1. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006, 55:451-458.
2. Kalialis L.V., Drzewiecki K.T., Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009, 19:275-282.
3. Ballestrero A., Boy D., Moran E., Cirmena G., Brossart P., Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 2008, 60:173-183.
4. Chiang C.L., Benencia F., Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010, 22:132-143.
5. Bolonaki I., Kotsakis A., Papadimitraki E., Aggouraki D., Konsolakis G., Vagia A., et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007, 25:2727-2734.
6. Domchek S.M., Recio A., Mick R., Clark C.E., Carpenter E.L., Fox K.R., et al. Telomerase-specific T-cell immunity in breastcancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007, 67:10546-10555.
7. Wenandy L., Sørensen R.B., Sengeløv L., Svane I.M., thor Straten P., Andersen M.H. The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 2008, 14:4-7.
8. Shay J.W., Wright W.E. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006, 5:577-584.
9. Harley C.B. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8:167-179.
10. Kim J.H., Park S.M., Kang M.R., Oh S.Y., Lee T.H., Muller M.T., et al. Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 2005, 19:776-781.
11. Pellicciotta I., Cortez-Gonzalez X., Sasik R., Reiter Y., Hardiman G., Langlade-Demoyen P., et al. Presentation of telomerase reverse transcriptase, a selftumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res 2008, 68:8085-8093.
12. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
13. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001, 50:3-15.
14. Matera L. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 2010, 36:131-141.
15. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006, 43:1284-1294.
16. Danet-Desnoyers G.A., Luongo J.L., Bonnet D.A., Domchek S.M., Vonderheide R.H. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 2005, 33:1275-1280.
17. Xiao B.G., Huang Y.M., Link H. Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases. BioDrugs 2003, 17:103-111.
18. Szabolcs P., Park K.D., Reese M., Marti L., Broadwater G., Kurtzberg J. Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method. Stem Cells 2003, 21:296-303.
19. Gannagé M., Abel M., Michallet A.S., Delluc S., Lambert M., Giraudier S., et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005, 174:8210-8218.
20. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
21. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
22. Oble D.A., Loewe R., Yu P., Mihm M.C. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3.
23. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
24. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002, 2:514-520.
25. Liu J.P., Chen W., Schwarer A.P., Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta 2010, 1805:35-42.
26. Piesche M., Hildebrandt Y., Zettl F., Chapuy B., Schmitz M., Wulf G., et al. Identification of a promiscuous HLA-DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum Immunol 2007, 68:572-576.
27. Fauce S.R., Yang O.O., Effros R.B. Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. J Immunol Methods 2007, 327:75-81.
28. Huttner K.G., Breuer S.K., Paul P., Majdic O., Heitger A., Felzmann T. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 2005, 54:67-77.
29. Camporeale A., Boni A., Iezzi G., Degl'Innocenti E., Grioni M., Mondino A., et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003, 63:3688-3694.
30. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006, 55:1553-1564.
31. Schroers R., Shen L., Rollins L., Rooney C.M., Slawin K., Sonderstrup G., et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 2003, 9:4743-4755.
32. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NYESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 2004, 101:9363-9368.
33. Tam J.P., Zavala F. Multiple antigen peptide: a novel approach to increase detection sensitivity of synthetic peptides in solid-phase immunoassays. J Immunol Methods 1989, 124:53-61.
34. Reynolds S.R., Dahl C.E., Harn D.A. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. J Immunol 1994, 152:193-200.
35. Brooks N.A., Pouniotis D.S., Sheng K.C., Apostolopoulos V., Pietersz G.A. A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice. Biochim Biophys Acta 2010, 1798:2286-2295.
36. Huang H.Q., Li S.C., Qin Z.H., Cao S.L., Yao Y., Liu Y.S., et al. Synthesis and bioactivities of two multiple antigen peptides as potential vaccine against schistosoma. Bioorg Med Chem Lett 2005, 15:2415-2419.
37. Kowalczyk W., de la Torre B.G., Andreu D. Strategies and limitations in dendrimeric immunogen synthesis, the influenza virus M2e epitope as a case study. Bioconjug Chem 2010, 21:102-110.
38. Gómara M.J., Fernández L., Pérez T., Ercilla G., Haro I. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection. Anal Biochem 2010, 396:51-58.
39. Sprague W.S., Pope M., Hoover E.A. Culture and comparison of feline myeloid dendritic cells vs macrophages. J Comp Pathol 2005, 133:136-145.
40. John J., Dalgleish A., Melcher A., Pandha H. Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination. J Immunol Methods 2005, 299:37-46.
41. Tsakiri A., Tsiantoulas D., Frederiksen J., Svane I.M. Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol 2010, 221:320-328.
42. Seager Danciger J., Lutz M., Hama S., Cruz D., Castrillo A., Lazaro J., et al. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods 2004, 288:123-134.
43. Carfí M., Bowe G., Ferrario D., Pieters R., Gribaldo L. Maintenance and characterization of lymphocytes in human long term bone marrow cultures to study immunotoxicity. Toxicol in Vitro 2010, 24:1395-1403.
44. Klapper J.A., Thomasian A.A., Smith D.M., Gorgas G.C., Wunderlich J.R., Smith F.O., et al. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 2009, 345:90-99.
45. Ullrich E., Ménard C., Flament C., Terme M., Mignot G., Bonmort M., et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 2008, 19:79-92.